Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design

Arno de Wilde; Ingrid S. van Maurik; Marleen Kunneman; Femke Bouwman; Marissa Zwan; Eline A J Willemse; Geert Jan Biessels; Mirella Minkman; Ruth Pel; Niki S M Schoonenboom; Ellen M A Smets; Mike P. Wattjes; Frederik Barkhof; Andrew Stephens; Erik J. van Lier; Richard Batrla-Utermann; Philip Scheltens; Charlotte E. Teunissen; Bart N M van Berckel; Wiesje M. van der Flier

doi:10.1016/j.dadm.2017.01.003

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design

Arno de Wilde^*, Ingrid S. van Maurik, Marleen Kunneman, Femke Bouwman, Marissa Zwan, Eline A J Willemse, Geert Jan Biessels, Mirella Minkman, Ruth Pel, Niki S M Schoonenboom, Ellen M A Smets, Mike P. Wattjes, Frederik Barkhof, Andrew Stephens, Erik J. van Lier, Richard Batrla-Utermann, Philip Scheltens, Charlotte E. Teunissen, Bart N M van Berckel, Wiesje M. van der Flier

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

INTRODUCTION: The Alzheimer's biomarkers in daily practice (ABIDE) project is designed to translate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cognitive impairment (MCI).

METHODS: ABIDE is a 3-year project with a multifaceted design and is structured into interconnected substudies using both quantitative and qualitative research methods.

RESULTS: Based on retrospective data, we develop personalized risk estimates for MCI patients. Prospectively, we collect MRI and CSF data from 200 patients from local memory clinics and amyloid PET from 500 patients in a tertiary setting, to optimize application of these tests in daily practice. Furthermore, ABIDE will develop strategies for optimal patient-clinician conversations.

DISCUSSION: Ultimately, this will result in a set of practical tools for clinicians to support the choice of diagnostic tests and facilitate the interpretation and communication of their results.

Original language	English
Pages (from-to)	143-151
Number of pages	9
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	6
DOIs	https://doi.org/10.1016/j.dadm.2017.01.003
Publication status	Published - 2017

Keywords

Alzheimer's disease
Biomarkers
Clinical practice
Dementia
Mild cognitive impairment

Access to Document

10.1016/j.dadm.2017.01.003

biomarkersFinal published version, 921 KBLicence: CC BY-NC-ND

Cite this

de Wilde, A., van Maurik, I. S., Kunneman, M., Bouwman, F., Zwan, M., Willemse, E. A. J., Biessels, G. J., Minkman, M., Pel, R., Schoonenboom, N. S. M., Smets, E. M. A., Wattjes, M. P., Barkhof, F., Stephens, A., van Lier, E. J., Batrla-Utermann, R., Scheltens, P., Teunissen, C. E., van Berckel, B. N. M., & van der Flier, W. M. (2017). Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 6, 143-151. https://doi.org/10.1016/j.dadm.2017.01.003

@article{d6c5a7588abb4f809dcdf148ec1ef3cc,

title = "Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design",

abstract = "INTRODUCTION: The Alzheimer's biomarkers in daily practice (ABIDE) project is designed to translate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cognitive impairment (MCI).METHODS: ABIDE is a 3-year project with a multifaceted design and is structured into interconnected substudies using both quantitative and qualitative research methods.RESULTS: Based on retrospective data, we develop personalized risk estimates for MCI patients. Prospectively, we collect MRI and CSF data from 200 patients from local memory clinics and amyloid PET from 500 patients in a tertiary setting, to optimize application of these tests in daily practice. Furthermore, ABIDE will develop strategies for optimal patient-clinician conversations.DISCUSSION: Ultimately, this will result in a set of practical tools for clinicians to support the choice of diagnostic tests and facilitate the interpretation and communication of their results.",

keywords = "Alzheimer's disease, Biomarkers, Clinical practice, Dementia, Mild cognitive impairment",

author = "{de Wilde}, Arno and {van Maurik}, {Ingrid S.} and Marleen Kunneman and Femke Bouwman and Marissa Zwan and Willemse, {Eline A J} and Biessels, {Geert Jan} and Mirella Minkman and Ruth Pel and Schoonenboom, {Niki S M} and Smets, {Ellen M A} and Wattjes, {Mike P.} and Frederik Barkhof and Andrew Stephens and {van Lier}, {Erik J.} and Richard Batrla-Utermann and Philip Scheltens and Teunissen, {Charlotte E.} and {van Berckel}, {Bart N M} and {van der Flier}, {Wiesje M.}",

year = "2017",

doi = "10.1016/j.dadm.2017.01.003",

language = "English",

volume = "6",

pages = "143--151",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

publisher = "John Wiley & Sons Inc.",

}

de Wilde, A, van Maurik, IS, Kunneman, M, Bouwman, F, Zwan, M, Willemse, EAJ, Biessels, GJ, Minkman, M, Pel, R, Schoonenboom, NSM, Smets, EMA, Wattjes, MP, Barkhof, F, Stephens, A, van Lier, EJ, Batrla-Utermann, R, Scheltens, P, Teunissen, CE, van Berckel, BNM & van der Flier, WM 2017, 'Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 6, pp. 143-151. https://doi.org/10.1016/j.dadm.2017.01.003

TY - JOUR

T1 - Alzheimer's biomarkers in daily practice (ABIDE) project

T2 - Rationale and design

AU - de Wilde, Arno

AU - van Maurik, Ingrid S.

AU - Kunneman, Marleen

AU - Bouwman, Femke

AU - Zwan, Marissa

AU - Willemse, Eline A J

AU - Biessels, Geert Jan

AU - Minkman, Mirella

AU - Pel, Ruth

AU - Schoonenboom, Niki S M

AU - Smets, Ellen M A

AU - Wattjes, Mike P.

AU - Barkhof, Frederik

AU - Stephens, Andrew

AU - van Lier, Erik J.

AU - Batrla-Utermann, Richard

AU - Scheltens, Philip

AU - Teunissen, Charlotte E.

AU - van Berckel, Bart N M

AU - van der Flier, Wiesje M.

PY - 2017

Y1 - 2017

N2 - INTRODUCTION: The Alzheimer's biomarkers in daily practice (ABIDE) project is designed to translate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cognitive impairment (MCI).METHODS: ABIDE is a 3-year project with a multifaceted design and is structured into interconnected substudies using both quantitative and qualitative research methods.RESULTS: Based on retrospective data, we develop personalized risk estimates for MCI patients. Prospectively, we collect MRI and CSF data from 200 patients from local memory clinics and amyloid PET from 500 patients in a tertiary setting, to optimize application of these tests in daily practice. Furthermore, ABIDE will develop strategies for optimal patient-clinician conversations.DISCUSSION: Ultimately, this will result in a set of practical tools for clinicians to support the choice of diagnostic tests and facilitate the interpretation and communication of their results.

AB - INTRODUCTION: The Alzheimer's biomarkers in daily practice (ABIDE) project is designed to translate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cognitive impairment (MCI).METHODS: ABIDE is a 3-year project with a multifaceted design and is structured into interconnected substudies using both quantitative and qualitative research methods.RESULTS: Based on retrospective data, we develop personalized risk estimates for MCI patients. Prospectively, we collect MRI and CSF data from 200 patients from local memory clinics and amyloid PET from 500 patients in a tertiary setting, to optimize application of these tests in daily practice. Furthermore, ABIDE will develop strategies for optimal patient-clinician conversations.DISCUSSION: Ultimately, this will result in a set of practical tools for clinicians to support the choice of diagnostic tests and facilitate the interpretation and communication of their results.

KW - Alzheimer's disease

KW - Biomarkers

KW - Clinical practice

KW - Dementia

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=85013119832&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2017.01.003

DO - 10.1016/j.dadm.2017.01.003

M3 - Article

C2 - 28239639

AN - SCOPUS:85013119832

VL - 6

SP - 143

EP - 151

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

ER -

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this